Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial with Tivantinib in Colorectal Cancer

[Business Wire] – TOKYO & WOBURN, Mass.–(BUSINESSWIRE)– Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. (Nasdaq: ARQL) today announced the top-line results of a randomized Phase 2 signal generation trial of … more

View todays social media effects on ARQL

View the latest stocks trending across Twitter. Click to view dashboard

See who ArQule is hiring next, click here to view